摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(Cyclobutylamino)-5,6-dichloro-1(beta-L-ribofuranosyl)-1H-benzimidazole | 176161-39-0

中文名称
——
中文别名
——
英文名称
2-(Cyclobutylamino)-5,6-dichloro-1(beta-L-ribofuranosyl)-1H-benzimidazole
英文别名
(2S,3S,4R,5S)-2-[5,6-dichloro-2-(cyclobutylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
2-(Cyclobutylamino)-5,6-dichloro-1(beta-L-ribofuranosyl)-1H-benzimidazole化学式
CAS
176161-39-0
化学式
C16H19Cl2N3O4
mdl
——
分子量
388.251
InChiKey
RORLSLUTIMMRHG-AJNGGQMLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    99.8
  • 氢给体数:
    4
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSES THERAPEUTIQUES
    申请人:THE WELLCOME FOUNDATION LIMITED
    公开号:WO1996001833A1
    公开(公告)日:1996-01-25
    (EN) The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.(FR) L'invention concerne des dérivés de benzimidazole ainsi que leur utilisation en thérapie médicale, notamment dans le traitement ou la prophylaxie d'infections virales telles que celles provoquées par les herpèsvirus. L'invention concerne également la préparation des dérivés de benzimidazole ainsi que des formulations pharmaceutiques les contenant.
    (中) 本发明涉及苯并咪唑生物及其在医学治疗中的应用,特别是用于治疗或预防由疱疹病毒引起的病毒感染。本发明还涉及苯并咪唑生物的制备以及含有它们的制药配方。
  • Therapeutic compounds
    申请人:——
    公开号:US20010003744A1
    公开(公告)日:2001-06-14
    The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.
    本发明涉及苯并咪唑生物及其在医疗治疗中的应用,特别是用于治疗或预防病毒感染,例如由疱疹病毒引起的感染。本发明还涉及苯并咪唑生物的制备以及含有它们的制药配方。
  • THERAPEUTIC COMPOUNDS
    申请人:THE WELLCOME FOUNDATION LIMITED
    公开号:EP0769017B1
    公开(公告)日:2000-05-24
  • US5998605A
    申请人:——
    公开号:US5998605A
    公开(公告)日:1999-12-07
  • US6077832A
    申请人:——
    公开号:US6077832A
    公开(公告)日:2000-06-20
查看更多

同类化合物

直链-苯并腺苷二磷酸酯 [(2R,3R,4R,5R)-2-(5,6-二氯苯并咪唑-1-基)-4-羟基-5-(羟基甲基)四氢呋喃-3-基]磷酸二氢酯 BENZIMIDAVIR苯并咪唑核苷 8-氨基-3-beta-D-呋喃核糖基咪唑并[4,5-g]喹唑啉 5,6-二甲基-1-(5-O-膦酰-alpha-D-呋喃核糖基)-1H-苯并咪唑 5,6-二氯-1-β-D-呋喃核糖基苯并咪唑 2-氯-5,6-二甲基-1-beta-D-呋喃核糖基苯并咪唑 2,5-哌嗪二酮,3-甲基-6-(2-甲基丙基)-,反-(9CI) 1,3-二去氮杂腺苷 (2S,3R,4S,5R)-2-(5,6-二甲基苯并咪唑-1-基)-5-(羟基甲基)四氢呋喃-3,4-二醇 2-amino-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole 2,5,6-trichloro-1-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyl)benzimidazole 1-(2',3',5'-tri-O-acetyl-α-D-lyxofuranosyl)-2,5,6-trichlorobenzimidazole Acetic acid (2R,3R,4R,5S)-4-acetoxy-5-acetoxymethyl-2-(2-bromo-5,6-dichloro-benzoimidazol-1-yl)-tetrahydro-furan-3-yl ester α-Ribazol-3'(2')-phosphorsaeureester 1-(2,3,5-tri-O-acetyl-α-L-lyxofuranosyl)-2,5,6-trichlorobenzimidazole 2'-Benzoyl-1-β-D-ribofuranosylbenzimidazol (1Ξ)-1-(5,6-dimethyl-benzimidazol-1-yl)-1,4-anhydro-L-arabitol 1-(6-acetylamino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-α-D-1-deoxy-ribofuranose 2-azido-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole 3'-Benzoyl-1-β-D-ribofuranosylbenzimidazol tri-O-acetyl-1-(8-methylsulfanyl-imidazo[4,5-g]quinazolin-1-yl)-β-D-1-deoxy-ribofuranose 3-aminopropyl-2'-(α-ribazolyl)-diphosphate 1-(6-acetylamino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-β-D-1-deoxy-ribofuranose 1-(6-amino-4-methylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-β-D-1-deoxy-ribofuranose 2-iodo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole Formamidoribosid 2-bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-L-ribofuranosyl)benzimidazole Formamidoribosid 5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole-2-thione 1-(tri-O-benzoyl-β-D-ribofuranosyl)-1,3-dihydro-benzoimidazole-2-thione 5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole bis(triethylammonium) salt 5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole triethylammonium salt tri-O-benzoyl-1-(2-methylsulfanyl-benzoimidazol-1-yl)-β-D-1-deoxy-ribofuranose 2-Allylthio-1-(β-D-ribofuranosyl)benzimidazol 1-benzoimidazol-1-yl-tri-O-benzoyl-α-D-1-deoxy-ribofuranose Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-(4,6-dichloro-2-thioxo-2,3-dihydro-benzoimidazol-1-yl)-tetrahydro-furan-3-yl ester 2-Chloro-6-bromo-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 6-amino-1-(tri-O-benzoyl-β-D-ribofuranosyl)-1,5-dihydro-imidazo[4,5-c]pyridine-4-thione Bis-5',5'- 1-(6-amino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-β-D-1-deoxy-ribofuranose (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(5,6-dimethoxy-1H-benzo[d]imidazol-1-yl)tetrahydrofuran-3,4-diyl diacetate 2-azido-4,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 2-bromo-4,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 2,4,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole 1-(2,3,5-Tri-O-acetyl-α-D-ribofuranosyl)-5,6-dimethyl-benzimidazol od. α-Ribazol-triacetat 2,4,6-trichloro-1-(2,3,5-tri-O-acetyl-α-D-ribofuranosyl)benzimidazole 2-bromo-6-trifluoromethyl-1-(5-deoxy-beta-D-ribofuranosyl)-1H-benzimidazole